During phase II trials, responses were more likely in patients with lung adenocarcinoma who were female, never-smokers, and of Asian origin; and it was not until 6 years later that EGFR mutations were published as biomarkers of response to EGFR inhibitors (17). This evidence concerns the gene EGFR and lung adenocarcinoma.